News

Zacks.com on MSN6h

LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints

LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.

Novo Nordisk: The Market Has Lost Its Mind

Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
sharewise3d

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...

The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Novo Nordisk: More Pain On The Horizon

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
Indianapolis Business Journal12h

Despite beating expectations, Lilly shares tumble after second-quarter earnings release

Novo Nordisk also released its second quarter results this week, boasting profit of more than $4 billion. Per-share earnings ...
Nasdaq23d

Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock? - Nasdaq

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and regulatory, that have led investors to bet against the company. The company ...

Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know

Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...